G Ciprandi1, M Cristofolini2, E Mira3. 1. IRCCS-A.O.U. San Martino di Genova, Genoa, Italy. E-mail: gio.cip@libero.it. 2. Istituto G.B. Mattei, Terme di Comano, Trento, Italy. 3. Clinica Otorinolaringoiatrica, Università di Pavia, Pavia, Italy.
Abstract
BACKGROUND: Comano thermal water, well known for its activity in the treatment of dermatological diseases, has been successfully employed in the treatment of upper airways disorders. OBJECTIVE: The present preliminary study aimed to evaluate whether Comano thermal water may be able to improve nasal symptoms severity in patients with allergic rhinitis (AR). METHODS: 30 AR patients were enrolled (mean age 40.9 years; 13 males) and treated with inhalation of Comano thermal water for 15 days. Total symptom score (TSS) and visual analogue scale (VAS) for patient's perception of nasal patency were assessed at baseline, after treatment, and after a 2-week follow-up. RESULTS: TSS significantly decreased after treatment as well as VAS significantly increased. The effects were partially long-lasting. CONCLUSION: Comano thermal water inhalation as monotherapy for AR was able to relieve nasal symptoms and patient's perception of nasal patency.
BACKGROUND: Comano thermal water, well known for its activity in the treatment of dermatological diseases, has been successfully employed in the treatment of upper airways disorders. OBJECTIVE: The present preliminary study aimed to evaluate whether Comano thermal water may be able to improve nasal symptoms severity in patients with allergic rhinitis (AR). METHODS: 30 AR patients were enrolled (mean age 40.9 years; 13 males) and treated with inhalation of Comano thermal water for 15 days. Total symptom score (TSS) and visual analogue scale (VAS) for patient's perception of nasal patency were assessed at baseline, after treatment, and after a 2-week follow-up. RESULTS: TSS significantly decreased after treatment as well as VAS significantly increased. The effects were partially long-lasting. CONCLUSION: Comano thermal water inhalation as monotherapy for AR was able to relieve nasal symptoms and patient's perception of nasal patency.
Authors: Giovanni Nicoletti; Marco Saler; Marco Mario Tresoldi; Angela Faga; Mattia Benedet; Mario Cristofolini Journal: J Int Med Res Date: 2019-10-10 Impact factor: 1.671